Gts Securities LLC Eli Lilly & CO Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$772.14 - $960.02 $7.03 Million - $8.74 Million	-9,100 Reduced 11.55%	69,700 $61.8 Million
Q2 2024 Aug 14, 2024	BUY	$724.87 - $909.04 $13.6 Million - $17 Million	18,700 Added 31.11%	78,800 $71.3 Million
Q1 2024 May 15, 2024	SELL	$592.2 - $792.28 $17.8 Million - $23.8 Million	-30,100 Reduced 33.37%	60,100 $46.8 Million
Q4 2023 Feb 14, 2024	SELL	$525.19 - $619.13 $7.77 Million - $9.16 Million	-14,800 Reduced 14.1%	90,200 $52.6 Million
Q3 2023 Nov 15, 2023	BUY	$434.7 - $599.3 $45.6 Million - $62.9 Million	105,000 New	105,000 $56.4 Million

4,011

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $740B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.